Cargando…

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

BACKGROUND: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. CASE: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santin, Alessandro D., Bellone, Stefania, Buza, Natalia, Schwartz, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175991/ https://www.ncbi.nlm.nih.gov/pubmed/28018954 http://dx.doi.org/10.1016/j.gore.2016.12.003

Ejemplares similares

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer
por: Perez, Edith A, et al.
Publicado: (2014)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
por: Levicki, Rea, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma
por: Ren, Yulan, et al.
Publicado: (2011)

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report
por: Hassanieh, Ihab, et al.
Publicado: (2018)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Spring, Laura M., et al.
Publicado: (2021)

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
por: Daniels, Benjamin, et al.
Publicado: (2021)

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
por: Taha, Zaid, et al.
Publicado: (2023)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
por: Cortés, Javier, et al.
Publicado: (2020)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
por: Moghaddas, Azadeh, et al.
Publicado: (2016)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
por: Vici, Patrizia, et al.
Publicado: (2017)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
por: Manthri, Sukesh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2q3lcvjigup236k88nk3pvnuan